drugset
drugset / Trial / NCT02674295

A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants

NCT02674295 ↗

Phase 1 Completed 8 enrolled Janssen Research & Development, LLC
RandomizedSingle-groupOpen-labelOther

Summary

The purpose of this study is to determine the metabolic disposition of radiolabeled esketamine administered by the oral and intravenous routes in healthy male participants.

Timeline

Start
2016-03
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 20 mg Oral
Subject Esketamine Other / unclassified 50 mg Oral

Indications

No indication recorded.